Lung Cancer
Volume 69, Issue 3 , Pages 315-318 , September 2010

Re-challenge chemotherapy for relapsed non-small-cell lung cancer

  • Tatsuya Nagano

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • ,
  • Young Hak Kim

      Affiliations

    • Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaharacho, Sakyo-ku, Kyoto 606-8507, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 75 751 3830; fax: +81 75 751 4643.
    • ,
  • Koichi Goto

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • ,
  • Kaoru Kubota

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • ,
  • Hironobu Ohmatsu

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • ,
  • Seiji Niho

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • ,
  • Kiyotaka Yoh

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • ,
  • Yoichi Naito

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • ,
  • Nagahiro Saijo

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan
    • ,
  • Yutaka Nishiwaki

      Affiliations

    • Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan

Received 22 July 2009 ,Revised 10 November 2009 ,Accepted 15 November 2009.

References 

  1. Novello S, Le Chevalier T. Chemotherapy for non-small-cell lung cancer. Part 1: early-stage disease. Oncology. 2003;17:357–364[Williston Park]
  2. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol. 2007;18:317–323
  3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92–98
  4. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996–3018.
  5. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol. 2000;18:2354–2362
  6. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O’Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000;18:2095–2103
  7. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol. 2004;22:1589–1597
  8. Kim E, Hirsh V, Mok T, Socinski M, Gervais R, Wu Y, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet. 2008;372:1809–1818
  9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132
  10. Hochhauser D, Harris AL. Drug resistance. Br Med Bull. 1991;47:178–196
  11. Sawyers CL. Where lies the blame for resistance – tumor or host?. Nat Med. 2007;13:1144–1145
  12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–216
  13. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007;99:1441–1454
  14. Zijlstra JG, de Vries EG, Mulder NH. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 1987;47:1780–1784
  15. Postmus PE, Berendsen HH, van Zandwijk N, Splinter TA, Burghouts JT, Bakker W. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 1987;23:1409–1411
  16. Giaccone G, Ferrati P, Donadio M, Testore F, Calciati A. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol. 1987;23:1697–1699

PII: S0169-5002(09)00593-5

doi: 10.1016/j.lungcan.2009.11.016

Lung Cancer
Volume 69, Issue 3 , Pages 315-318 , September 2010

Article Tools

* Image Usage & Resolution